In vitro characterization and performance testing of the ension pediatric cardiopulmonary assist system.
In vitro characterization and performance testing of the ension pediatric cardiopulmonary assist system.
复制标题
DOI：
10.1097/mat.0b013e3181909d76
复制
发表时间：
2009-05
期刊：
影响因子：
--
通讯作者：
Gartner M
中科院分区：
文献类型：
--
作者：
Pantalos GM;Horrell T;Merkley T;Sahetya S;Speakman J;Johnson G;Gartner M
In the last forty years, mechanical circulatory support devices have become an effective option for the treatment of end stage heart failure in adults. Few possibilities, however, are available for pediatric cardiopulmonary support. Ension Inc. (Pittsburgh, PA) is developing a pediatric cardiopulmonary assist system (pCAS) intended to address the limitations of existing devices used for this patient population. The pCAS device is an integrated unit containing an oxygenator and pump within a single casing, significantly reducing the size and blood-contacting surface area in comparison to current devices. Prototype pCAS devices produce appropriate flows and pressures while minimizing priming volume and preparation time. The pCAS was tested on a mock circulation designed to approximate the hemodynamic parameters of a small infant using a 10 Fr. ECMO inflow cannula and an 8 Fr. ECMO outflow cannula. Revision 4 of the device provided a flow rate of 0.42 L/min at 6500 RPM. Revision 5, featuring improved impeller and diffuser designs, provided a flow rate of 0.57 L/min at 5000 RPM. The performance tests indicate that for this cannulae combination, the pCAS pump is capable of delivering sufficient flows for patients less than 5 kg.
